Cystic Neoplasm — Variants & evidence

Cystic Neoplasm — Variants & evidence · CancerIndex

Variants & evidence

Curated clinical evidence by variant and therapy

4 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.

civicCuratedShowing 1–4 of 4 evidence items (4 on this page mapped to a descendant entity) · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
CCNE1 Amplification1
Akt Inhibitor MK2206 + DinaciclibCombination	Ovarian Serous Cystadenocarcinoma	Predictive	D	Supports Sensitivity Response	4	accepted	EID1735 A high throughput compound screen identified synergistic combinations in CCNE1 amplified high grade serous ovarian carcinoma, including dinaciclib and AKT inhibitors PMID 27663592 · Au-Yeung et al., 2017 · Open in CIViC	civic
CTNNB1 Exon 3 Mutation3
(diagnostic)	Adamantinomatous CraniopharyngiomaALIAS	Diagnostic	B	Supports Positive	4	submitted	EID12111 Assessment of beta-catenin mutations in a large collections of pituitary adenomas (n=60) and craniopharynangiomas (n=41), identified CTNNB1 exon 3 mutations in 77% of craniopharynangiomas, all of the … (full text at CIViC) PMID 15891929 · Buslei et al., 2005 · Open in CIViC	civic
〃	Adamantinomatous CraniopharyngiomaALIAS	Diagnostic	B	Supports Positive	4	submitted	EID12112 Whole-exome sequencing identified CTNNB1 mutations in 11 of 12 (92%) of adamantinomatous craniopharyngiomas examined. No other recurrent mutations or genomic aberrations were identified. Targeted se… (full text at CIViC) PMID 24413733 · Brastianos et al., 2014 · Open in CIViC	civic
〃	Adamantinomatous Craniopharyngioma

Data updated 22 hours agoSource updated unknownsource: civic (CC0)

Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.